CN112089055A - 减压舒眠益生菌组合物 - Google Patents
减压舒眠益生菌组合物 Download PDFInfo
- Publication number
- CN112089055A CN112089055A CN202011004489.1A CN202011004489A CN112089055A CN 112089055 A CN112089055 A CN 112089055A CN 202011004489 A CN202011004489 A CN 202011004489A CN 112089055 A CN112089055 A CN 112089055A
- Authority
- CN
- China
- Prior art keywords
- gaba
- lactobacillus paracasei
- sleep
- gamma
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 23
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 17
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 128
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 64
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 34
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 230000006837 decompression Effects 0.000 claims abstract description 5
- 235000013336 milk Nutrition 0.000 claims description 10
- 239000008267 milk Substances 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000013589 supplement Substances 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 235000008452 baby food Nutrition 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000021185 dessert Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000019985 fermented beverage Nutrition 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000011496 sports drink Nutrition 0.000 claims description 2
- 235000015192 vegetable juice Nutrition 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000003860 sleep quality Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000003340 mental effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 230000001590 oxidative effect Effects 0.000 abstract description 2
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 description 15
- 230000036506 anxiety Effects 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000007958 sleep Effects 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 230000036578 sleeping time Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- BWSIKGOGLDNQBZ-LURJTMIESA-N (2s)-2-(methoxymethyl)pyrrolidin-1-amine Chemical compound COC[C@@H]1CCCN1N BWSIKGOGLDNQBZ-LURJTMIESA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了减压舒眠益生菌组合物，属于益生菌的所有相关食品产业领域。它包括副干酪乳杆菌和γ‑氨基丁酸(GABA)。本发明中减压舒眠益生菌组合物组合物，作为减轻压力、提高睡眠质量的食品补充或药物的方法，即为使用减压舒眠益生菌组合物组合物可作为提升对抗环境中氧化压力、减轻运动训练的机体疲劳压力、舒缓精神压力、提高睡眠质量之食品补充或药物。
Description
技术领域
本发明涉及减压舒眠益生菌组合物，属于益生菌的所有相关食品产业领域。
背景技术
人体与肠道内的微生物有着紧密的共生关系（symbiosis），影响着人体消化吸收、免疫调节、代谢调节***的运作；其中益生菌（probiotics）是一类对人体有帮助的微生物菌群，当食用足够的剂量时，某些益生菌能够产生和传递神经活性物质，如γ-氨基丁酸（GABA）、血清素（serotonin，5-HT）等，他们作用于脑肠轴（gut-brain axis），显著影响焦虑、抑郁症、压力、自闭症、睡眠等精神相关疾病或症状（Dinan TG et al., 2013）。
睡眠，是指当大脑皮质内抑制性神经递质作用大于兴奋性神经递质作用时的结果。睡眠障碍经常与焦虑症相关，并可能构成焦虑症的核心特征。临床治疗上，针对失眠和其他睡眠障碍的干预措施与用于治疗焦虑障碍的干预措施之间存在大量重叠。长期处于睡眠障碍的人，极大地影响人体的免疫能力和认知能力，并诱发其他潜在的神经失调疾病，进而影响其在家庭和工作中各方面的人际关系（Mellman T A, 2006）。
研究人员对于加速老化鼠（senescence accelerated mouse prone 8 mice,SAMP8）进行旷野实验（open field test），一般焦虑的囓齿类动物倾向于在旷野周边活动，如果在场地中央部分的次数和时间增加，表示焦虑程度减轻, 或活动力增加(神经退化减低)。研究表明，长期食用副干酪乳杆菌Lactobacillus paracasei PS23之老化鼠移动的总距离增加，停留着场地中央部分的时间增长，揭示其焦虑程度比没有食用PS23的老鼠显著降低（Huang S Y, 2018）。
研究表明，给加速衰老小鼠连续补充活的或是热灭活的副干酪乳杆菌 PS23，可以提高肌肉中SOD和GPx的表达水平，减轻机体的氧化压力；补充 PS23可降低血清中的皮质酮（corticosterone）和提升多巴胺（dopamine, DA），血清素和脑源性神经营养因子（brain-derived neurotrophy factor, BDNF），增加神经可塑性和存活，从而改善焦虑行为，提高认知能力（Liao J-F, 2019）。焦虑与睡眠息息相关，睡眠障碍是构成焦虑症的核心特征（Mellman T A, 2006）。 因此食用PS23能显著帮助机体，减轻氧化压力、改善焦虑状况，提高认知能力和睡眠质量（Huang S Y, 2018）。
在哺乳动物中，GABA是中枢神经***中非常重要的抑制性神经传达物质，约50%的中枢神经突触部位以GABA为递质，当大脑皮质内抑制性神经递质作用大于兴奋性神经递质作用时，大脑活动就逐渐表现为睡眠状态（Boonstra E, 2015）。大脑中足够的GABA会让人感到轻松快乐，缓解压力，提高睡眠质量；含量过低则可能导致焦虑、紧张、抑郁、失眠。现代社会发展迅猛，使得长久处于高压力族群如白领上班族、运动员、设计师等，容易缺乏GABA需要及时补充以便舒缓情绪。
研究表明，人体中的GABA自我合成的比较少，主要靠后天食物获取，且食物获取的吸收利用度没有营养补充剂利用度高，因此GABA作为食品补充剂的方式被摄取，对人体实现减压舒眠，具有十分重要的意义。GABA作为被国家批准为新资源食品原料，有着其他产品原料无法代替的天然功能性，被广泛应用在保健食品、功能性食品及饮料、甚至是药物中。目前市面上的助眠产品大多作用原理单一，化学合成有毒副作用，容易产生药物依赖，不利于人体的健康。因此，需要开发一种能长期服用的，能够通过减轻精神压力、改善焦虑状况、提升自身免疫力、清除氧化自由基、缓解脑部疲劳、添加神经抑制剂等方法合并运用减轻身体疲劳压力，氧化压力，缓解精神压力和焦虑，为改善睡眠质量相关市场提供一个全方位的解决方案。
发明内容
本发明所要解决的技术问题在于：提供减压舒眠益生菌组合物，它可用于同时增加机体的抗氧化与抗发炎因子，解决抗衰老相关市场上急需解决的问题。
本发明所要解决的技术问题采取以下技术方案来实现：
减压舒眠益生菌组合物，包括副干酪乳杆菌和γ-氨基丁酸（GABA），所述副干酪乳杆菌合并γ-氨基丁酸（GABA）有效量为每日补充100亿～500亿，即1010 cfu/day～5*1010 cfu/day的副干酪乳杆菌菌量和每日0.5克～2.5克GABA。
作为优选实例，所述副干酪乳杆菌为副干酪乳杆菌PS 23。
作为优选实例，所述副干酪乳杆菌合并γ-氨基丁酸（GABA）的有效量为每日补充100亿，即1010 cfu/day的副干酪乳杆菌菌量和每日0.5克 γ-氨基丁酸（GABA）。
作为优选实例，所述副干酪乳杆菌合并γ-氨基丁酸（GABA）可进一步包括药学上可接受之载剂、赋形剂或稀释剂；并可进一步制成流体乳品、浓缩牛奶、优酪乳、酸乳、冷冻优格、乳杆菌发酵饮料、奶粉、冰淇淋、乳酪、干酪、豆浆、发酵豆浆、蔬果汁、果汁、运动饮料、甜点、果冻、糖果、婴儿食品、健康食品、动物饲料、中草药组合物或膳食补充品。
本发明的有益效果是：本发明中的副干酪乳杆菌合并GABA，通过益生菌与人类共生之“脑肠轴”机制，并组合天然神经抑制剂GABA，是一种能长期服用的，能够通过减轻精神压力、改善焦虑状况、提升自身免疫力、清除氧化自由基、缓解脑部疲劳、添加神经抑制剂等方法合并运用减轻身体疲劳压力，氧化压力，缓解精神压力和焦虑，为改善睡眠质量相关市场提供一个多元的，有效的，安全的全方位的解决方案。
具体实施方式
为了对本发明的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施例，进一步阐述本发明。
实施例一
减压舒眠益生菌组合物，包括副干酪乳杆菌和γ-氨基丁酸（GABA），所述副干酪乳杆菌合并γ-氨基丁酸（GABA）的有效量为每日补充100亿，即1010 cfu/day的副干酪乳杆菌菌量和每日0.5克γ-氨基丁酸（GABA）。
实施例二
减压舒眠益生菌组合物，包括副干酪乳杆菌和γ-氨基丁酸（GABA），所述副干酪乳杆菌合并γ-氨基丁酸（GABA）的有效量为每日补充200亿，即2*1010 cfu/day的副干酪乳杆菌菌量和每日1.0克γ-氨基丁酸（GABA）。
实施例三
减压舒眠益生菌组合物，包括副干酪乳杆菌和γ-氨基丁酸（GABA），所述副干酪乳杆菌合并γ-氨基丁酸（GABA）的有效量为每日补充300亿，即3*1010 cfu/day的副干酪乳杆菌菌量和每日1.5克γ-氨基丁酸（GABA）。
实施例四
减压舒眠益生菌组合物，包括副干酪乳杆菌和γ-氨基丁酸（GABA），所述副干酪乳杆菌合并GABA的有效量为每日补充400亿，即4*1010 cfu/day的副干酪乳杆菌菌量和每日2.0克γ-氨基丁酸（GABA）。
实施例五
减压舒眠益生菌组合物，包括副干酪乳杆菌和γ-氨基丁酸（GABA），所述副干酪乳杆菌合并γ-氨基丁酸（GABA）的有效量为每日补充500亿，即5*1010 cfu/day的副干酪乳杆菌菌量和每日2.5克γ-氨基丁酸（GABA）。
研究方法及进行步骤
1.临床试验
选取60名年龄在18-80岁的重度失眠患者，男女不限，未接受过类似的测试，1年内未服用过与减压助眠有关的药品或保健食品；随机分为试验组50例和对照组10例，试验组按照上述五个实施例（每组10例）服用本品，对照组服用安慰剂；连续试用一个月，试用期间不使用其它治疗失眠的中西药物及疗法，观察试验者一个月后的睡眠状态；
疗效判断标准：
(1)显效:睡眠明显好转，睡眠时间较试验前增加3小时及以上，入睡时间缩短至半小时以内；
(2)有效:症状减轻，睡眠时间较试验前增加不足3小时，入睡时间缩短至半小时至1小时间之间；
(3)无效:较试验前失眠症状并无改善；
按照以上失眠疗效标准观察效果，结果表明，本发明的组合物有显著改善睡眠质量的作用。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (4)
1.减压舒眠益生菌组合物，其特征在于：包括副干酪乳杆菌合并γ-氨基丁酸（GABA），所述副干酪乳杆菌和γ-氨基丁酸（GABA）有效量为每日补充100亿～500亿，即1010 cfu/day～5*1010 cfu/day的副干酪乳杆菌菌量和每日0.5克～2.5克γ-氨基丁酸（GABA）。
2.根据权利要求1所述的减压舒眠益生菌组合物，其特征在于：所述副干酪乳杆菌为副干酪乳杆菌PS 23 。
3.根据权利要求1所述的减压舒眠益生菌组合物，其特征在于：所述副干酪乳杆菌合并GABA的有效量为每日补充100亿，即1010 cfu/day的副干酪乳杆菌菌量和每日0.5克γ-氨基丁酸（GABA）。
4.根据权利要求1所述的减压舒眠益生菌组合物，其特征在于：所述副干酪乳杆菌合并γ-氨基丁酸（GABA）可进一步包括药学上可接受之载剂、赋形剂或稀释剂；并可进一步制成流体乳品、浓缩牛奶、优酪乳、酸乳、冷冻优格、乳杆菌发酵饮料、奶粉、冰淇淋、乳酪、干酪、豆浆、发酵豆浆、蔬果汁、果汁、运动饮料、甜点、果冻、糖果、婴儿食品、健康食品、动物饲料、中草药组合物或膳食补充品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011004489.1A CN112089055A (zh) | 2020-09-22 | 2020-09-22 | 减压舒眠益生菌组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011004489.1A CN112089055A (zh) | 2020-09-22 | 2020-09-22 | 减压舒眠益生菌组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112089055A true CN112089055A (zh) | 2020-12-18 |
Family
ID=73754952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011004489.1A Pending CN112089055A (zh) | 2020-09-22 | 2020-09-22 | 减压舒眠益生菌组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112089055A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112716984A (zh) * | 2021-01-25 | 2021-04-30 | 广东南芯医疗科技有限公司 | 副干酪乳杆菌L.p R3-10在制备缓解焦虑、改善睡眠药物中的应用 |
| CN113995139A (zh) * | 2021-10-28 | 2022-02-01 | 驻马店华中正大有限公司 | 一种益生菌组合物及其应用 |
| CN114586985A (zh) * | 2022-03-16 | 2022-06-07 | 黑龙江省科学院高技术研究院 | γ－氨基丁酸在制备缓解精神***症患者焦虑情绪的食品中的应用及制备的食品 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105725216A (zh) * | 2016-03-15 | 2016-07-06 | 天津普生源科技发展有限公司 | 一种含有gaba的助眠功能食品及其制备方法 |
| CN106071436A (zh) * | 2016-06-12 | 2016-11-09 | 中国食品发酵工业研究院 | 一种能够改善睡眠质量的芦笋发酵饮品及其制备方法 |
| WO2018073963A1 (ja) * | 2016-10-21 | 2018-04-26 | 森永乳業株式会社 | 気分プロフィール改善剤 |
| JP2019112328A (ja) * | 2017-12-22 | 2019-07-11 | キリン株式会社 | 概日リズム改善用組成物 |
| US20200078421A1 (en) * | 2018-09-11 | 2020-03-12 | Direct Digital, LLC DBA Adaptive Health | Nutritional supplements and therapeutic compositions comprising probiotics |
| CN111248442A (zh) * | 2020-03-03 | 2020-06-09 | 上海泓商生物科技有限公司 | 抗衰老益生菌 |
| CN111511378A (zh) * | 2017-12-19 | 2020-08-07 | 杜邦营养生物科学有限公司 | 用于认知和心理健康的益生菌 |
-
2020
- 2020-09-22 CN CN202011004489.1A patent/CN112089055A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105725216A (zh) * | 2016-03-15 | 2016-07-06 | 天津普生源科技发展有限公司 | 一种含有gaba的助眠功能食品及其制备方法 |
| CN106071436A (zh) * | 2016-06-12 | 2016-11-09 | 中国食品发酵工业研究院 | 一种能够改善睡眠质量的芦笋发酵饮品及其制备方法 |
| WO2018073963A1 (ja) * | 2016-10-21 | 2018-04-26 | 森永乳業株式会社 | 気分プロフィール改善剤 |
| CN111511378A (zh) * | 2017-12-19 | 2020-08-07 | 杜邦营养生物科学有限公司 | 用于认知和心理健康的益生菌 |
| JP2019112328A (ja) * | 2017-12-22 | 2019-07-11 | キリン株式会社 | 概日リズム改善用組成物 |
| US20200078421A1 (en) * | 2018-09-11 | 2020-03-12 | Direct Digital, LLC DBA Adaptive Health | Nutritional supplements and therapeutic compositions comprising probiotics |
| CN111248442A (zh) * | 2020-03-03 | 2020-06-09 | 上海泓商生物科技有限公司 | 抗衰老益生菌 |
Non-Patent Citations (2)
| Title |
|---|
| SHIH-YI HUANG，等: "Lactobacillus paracasei PS23 Delays Progression of Age-Related Cognitive Decline in Senescence Accelerated Mouse Prone 8 (SAMP8) Mice", 《NUTRIENTS》 * |
| 江省蓉: "《图解保健食品全书》", 31 May 2015, 湖南科学技术出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112716984A (zh) * | 2021-01-25 | 2021-04-30 | 广东南芯医疗科技有限公司 | 副干酪乳杆菌L.p R3-10在制备缓解焦虑、改善睡眠药物中的应用 |
| CN112716984B (zh) * | 2021-01-25 | 2022-07-08 | 广东南芯医疗科技有限公司 | 副干酪乳杆菌L.p R3-10在制备缓解焦虑、改善睡眠药物中的应用 |
| CN113995139A (zh) * | 2021-10-28 | 2022-02-01 | 驻马店华中正大有限公司 | 一种益生菌组合物及其应用 |
| CN114586985A (zh) * | 2022-03-16 | 2022-06-07 | 黑龙江省科学院高技术研究院 | γ－氨基丁酸在制备缓解精神***症患者焦虑情绪的食品中的应用及制备的食品 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210008130A1 (en) | Methods and compositions using bifidobacterium longum to treat or prevent depressive symptoms | |
| CN112089055A (zh) | 减压舒眠益生菌组合物 | |
| Dudek-Wicher et al. | Clinical trials of probiotic strains in selected disease entities | |
| CN105025909B (zh) | 应激减轻剂 | |
| US20210060096A1 (en) | Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances | |
| US11825856B2 (en) | Composition for preventing or improving functional gastrointestinal disorders, and, pharmaceutical composition, food/beverage composition, and method of preventing or improving functional gastrointestinal disorders using the composition for preventing or improving functional gastrointestinal disorders | |
| CN107568736A (zh) | 解酒醒酒医学配方食品 | |
| KR102397589B1 (ko) | 신규한 락토바실러스 퍼멘텀 ｍｓｋ４０８ 균주 및 이를 포함하는 뇌전증의 예방 또는 치료용 조성물 | |
| JP7130287B2 (ja) | プロバイオティクス組成物の製造方法 | |
| Rocks et al. | Possible use of fermented foods in rehabilitation of anorexia nervosa: the gut microbiota as a modulator | |
| JP2023133435A (ja) | 睡眠促進用組成物並びに該睡眠促進用組成物を用いた医薬品組成物及び飲食品組成物 | |
| CN108968037A (zh) | 老年痴呆症全营养配方食品 | |
| CN107319550A (zh) | 脑外伤全营养配方食品 | |
| Attri et al. | Probiotics and their potential applications: an introduction | |
| WO2022196488A1 (ja) | Ｑｏｌを改善するための組成物 | |
| KR20210102916A (ko) | 인지 및 정신 건강을 위한 프로바이오틱스 | |
| Georgieva et al. | Probiotics: past, present, and future challenges | |
| Salama et al. | Advancement of yogurt production technology | |
| JP2021045054A (ja) | 抗憂うつ用組成物、幸福感向上用組成物 | |
| Kusich | A functional application of the Gut-Brain Axis: a proposed Nutrition intervention for the treatment of Depression | |
| JP7523493B2 (ja) | 情動的反応を制御するため、並びに潜在的な気分変調の治療及び予防のための、ビフィドバクテリウム・ロンガムを用いる、方法及び組成物 | |
| Larkin et al. | Probiotics and depression | |
| Michael et al. | Chapter-5 Probiotics | |
| Nicolson et al. | Dietary considerations for patients with chronic illnesses and multiple chronic infections | |
| Churat et al. | Preliminary study of probiotics in reducing common cold in children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201218 |